Table 2.
Quality assessment of eligible studies Newcastle–Ottawa scale (NOS) score
| Author | Country | Selection | Comparability | Outcome | Total | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Adequate of case definition | Representativeness of the cases | Selection of Controls | Definition of Controls | Comparability of cases and controls | Ascertainment of exposure | Same method of ascertainment | Non-Response rate | |||
| Wei L 2019 | China | * | * | * | * | * | * | * | * | 8a |
| Cui Y 2017 | China | * | * | * | * | * | * | * | * | 8a |
| Li XM 2020 | China | * | * | * | * | * | - | * | * | 7c |
| Zhang HY 2017 | China | * | * | * | * | * | - | * | * | 7c |
| Li CL 2019 | China | * | * | * | * | * | * | * | - | 7c |
| Yang XH 2021 | China | * | * | * | * | * | * | * | - | 7c |
| Kang BJ 2021 | China | * | * | * | * | * | * | * | - | 7c |
| Zhao LJ 2021 | China | * | * | * | * | * | * | * | - | 7c |
| Shi JD 2019 | China | * | * | * | * | * | * | * | * | 8a |
| Zhao SS 2020 | China | * | * | * | * | * | * | * | - | 7b |
| Wang F 2021 | China | * | * | * | * | * | * | * | * | 8a |
| Gao N 2020 | China | * | * | * | * | * | * | - | - | 6ab |
| Dong Z 2020 | China | * | * | * | * | * | - | * | - | 6abd |
| Geng H 2020 | China | * | * | * | * | * | * | * | * | 8a |
| Liang R 2018 | China | * | * | * | * | * | * | * | * | 8a |
| Pang LL 2019 | China | * | * | * | * | * | * | * | - | 7c |
| Li LP 2020 | China | * | * | * | * | * | - | * | - | 6bd |
| Chen CH 2018 | China | * | * | * | * | * | * | * | * | 8a |
| Wang RX 2020 | China | * | * | * | * | * | - | * | - | 6bd |
| Liu SX 2019 | China | * | * | * | * | * | * | * | * | 8a |
| Huang YS 2022 | China | * | * | * | * | * | * | * | * | 8a |
| Wang Y 2019 | China | * | * | * | * | * | * | - | - | 6bd |
| Wang S 2018 | China | * | * | * | * | * | - | * | - | 6bd |
| Guo LF 2018 | China | * | * | * | * | * | * | * | - | 7c |
| Huang YF 2021 | China | * | * | * | * | * | * | * | * | 8a |
| Zhang NN 2021 | China | * | * | * | * | * | * | * | * | 8a |
| Chen XL 2020 | China | * | * | * | * | * | * | * | * | 8a |
| Ma XR 2019 | China | * | * | * | * | * | * | * | * | 8a |
| Dong YZ 2018 | China | * | * | * | * | * | - | * | - | 6ad |
| Cui HX 2018 | China | * | * | * | * | * | * | * | * | 8a |
| Han PF 2021 | China | * | * | * | * | ** | * | * | * | 9 |
| Jin B 2018 | China | * | * | * | * | * | * | * | * | 8a |
| Li Y 2022 | China | * | * | * | * | * | * | * | - | 7cd |
| Han W 2018 | China | * | * | * | * | ** | * | * | * | 9 |
| Zhang ZW 2021 | China | * | * | * | * | * | * | * | * | 8a |
| Fan HJ 2021 | China | * | * | * | * | ** | * | * | * | 9 |
| Jin LL 2019 | China | * | * | * | * | * | - | * | - | 6bd |
| Chen ZY 2017 | China | * | * | * | * | * | * | * | * | 8a |
| Wang XL 2020 | China | * | * | * | * | * | * | * | - | 7cd |
aOnly univariate analysis was performed, and data for multivariate analysis were lacking
bThe article only provides data on survival prognosis and does not provide clinical pathological parameters
cLack of data on survival prognosis, only clinicopathological parameters were provided
dFewer cases